Edgar Filing: ABIOMED INC - Form SD

ABIOMED INC Form SD May 24, 2018

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM SD

**Specialized Disclosure Report** 

## ABIOMED, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware 001-09585 04-2743260 (State or other jurisdiction (Commission (IRS Employer

of incorporation) File Number) Identification No.)

22 Cherry Hill Drive, Danvers, Massachusetts 01923
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code (978) 646-1400

Todd A. Trapp

# Edgar Filing: ABIOMED INC - Form SD

## 978-646-1400

| (Name and telephone number, including area code, of the person to contact in connection with this re | eport) |
|--|--------|
|--|--------|

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

### **Section 1** Conflict Minerals Disclosure

# Item 1.01 Conflict Minerals Disclosure and Report Conflict Minerals Disclosure

This Form SD of ABIOMED, Inc. (the Company) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2017 to December 31, 2017.

A copy of our Conflict Minerals Report is filed herewith as Exhibit 1.01 hereto and is publicly available at: www.abiomed.com.

Information appearing on www.abiomed.com is not a part of, and is not incorporated by reference into, this Form SD.

### Item 1.02 Exhibit

The Company is hereby filing its Conflict Minerals Report described in Item 1.01 as Exhibit 1.01 to this Report.

### Section 2 Exhibits

### Item 2.01 Exhibits

The following exhibit is filed as part of this report:

Exhibit 1.01 Conflict Minerals Report for the calendar year ended December 31, 2017.

# Edgar Filing: ABIOMED INC - Form SD

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 24, 2018 ABIOMED, INC.

(Registrant)

By: /s/ Todd A. Trapp
Todd A. Trapp
Vice President, Chief Financial Officer